

DATE:	31 March 2025
TO:	All Zones: Physicians, Nurses, Healthcare Providers, Laboratory Staff
FROM:	Clinical Biochemistry and External Send Outs
RE:	Discontinuation of Serum and CSF Cancer Associated Autoantibody Panel Testing

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- Effective March 31, 2025, serum and cerebrospinal fluid *Cancer Associated Autoantibody Panel* Testing will be discontinued provincially.

Background

- Cancer Associated Autoantibody Panel REF* is a lab developed external send out test for cancer. Due to poor evidence base for the clinical use of this low volume test, Alberta Precision Laboratories will not approve send out for *Cancer Associated Autoantibody Panel* testing.
- Superior performing genetic and pathology tests are available in Alberta for cancer.

How this will impact you

- Serum and CSF *Cancer Associated Autoantibody Panel* testing will be discontinued and removed from Connect Care, test directories, and the Alberta Mitogen requisition.
- If the lab receives a requisition requesting *Cancer Associated Autoantibody Panel Test*, the test order will be cancelled as "Not available in Alberta".

Action Required

- Remove *Cancer Associated Autoantibody Panel REF* from preference lists.

Questions/Concerns

- Dr. Kareena Schnabl, Clinical Biochemist, University of Alberta Hospital, (780) 407-3186 or Kareena.Schnabl@aplabs.ca
- Dr. Allison Venner, Clinical Biochemistry Section Chief, South Sector, 403-770-3566, allison.venner@albertaprecisionlabs.ca

Approved by

- Dr. Carolyn O'Hara, Interim Chief Medical Laboratory Officer, APL